HTA & Market Access

32 Items

This section focuses on health technology assessment, economic evaluation, reimbursement, and policy, addressing the clinical, economic, and societal value of health technologies to support evidence‑based pricing, access, and sustainable healthcare decision‑making.

Section Editor: Roberto Ravasio
More Than Access Srl Società Benefit, HEOR & RWE | Milan, Italy

All Items

A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy Analisi di budget impact del biosimilare di pegfilgrastim nel trattamento della neutropenia febbrile in Italia

Roberto Ravasio, Lorenzo Antonuzzo, Marco Danova, Paolo Pronzato

4-8

DOI: https://doi.org/10.33393/abtpn.2020.2030
The value of obinutuzumab for untreated advanced Follicular Lymphoma: an assessment based on Multicriteria Decision Analysis (MCDA)

Claudio Jommi, Roberto Ravasio

78-85

DOI: https://doi.org/10.33393/abtpn.2019.302
Getting your devices ready for MDR compliance – a clinical approach and orthopaedic device manufacturers’ perspective

Peter Fennema, Hassan Achakri

70-75

DOI: https://doi.org/10.33393/abtpn.2019.294
Lean Management: organizational innovations in hematological Day-Hospitals Lean Management: innovazioni organizzative nei Day Hospital Ematologici

Caterina Bianciardi, Jacopo Guercini

62-69

DOI: https://doi.org/10.33393/abtpn.2019.290
Performance indicators for monitoring the integrated care pathway of patients with colorectal cancer: the E.Pic.A. project Performance indicators for colorectal cancer

Andrea Ricotti, Giovanni Messori Ioli, Mattia Altini, Letizia Bachini, William Balzi, Giovanni Luca Frassineti, Fabrizio Gemmi, Ilaria Massa, Andrea Pierini, Oscar Bertetto, Patrizia Racca

48-54

DOI: https://doi.org/10.33393/abtpn.2019.292
Key performance indicators for monitoring the integrated care pathway in breast cancer: the E.Pic.A. project

Mattia Altini, William Balzi, Roberta Maltoni, Fabio Falcini, Flavia Foca, Giovanni Messori Ioli, Andrea Ricotti, Oscar Bertetto, Marinella Mistrangelo, Gianni Amunni, Fabrizio Gemmi, Letizia Bachini, Andrea Silenzi, Roberta Pastorino, Andrea Barbara, Andrea Pierini, Ilaria Massa

31-38

DOI: https://doi.org/10.33393/abtpn.2019.291
A Budget impact analysis of adalimumab biosimilar: the Italian context Analisi di budget impact del biosimilare di adalimumab: lo scenario italiano

Roberto Ravasio, Silvio Mazzi, Maria Esposito, Gionata Fiorino, Alberto Migliore

16-23

DOI: https://doi.org/10.33393/abtpn.2019.280

Previous 26-50 of 32